Air classifier technology (ACT) in dry powder inhalation: Part 4. Performance of air classifier technology in the Novolizer® multi-dose dry powder inhaler

International Journal of Pharmaceutics

Volumn 310, Issue 1-2, 2006, Pages 81-89

  De Boer, A H ^a   Hagedoorn, P ^a   Gjaltema, D ^a   Goede, J ^b   Frijlink, H W ^a  

^a UNIVERSITY OF GRONINGEN   (Netherlands)

^b VIATRIS GmbH and Co KG   (Germany)

Author keywords

Adhesive mixtures; Air classifier technology; Carrier lactose; Dry powder inhalation; Fine particle fraction; Novolizer

Indexed keywords

BUDESONIDE; DRUG CARRIER; FORMOTEROL FUMARATE; LACTOSE; SALBUTAMOL SULFATE;

ACCURACY; ANALYTIC METHOD; ARTICLE; BULK DENSITY; DISPERSION; DRUG FORMULATION; DRY POWDER; FLOW RATE; INHALER; PARTICLE SIZE; PRIORITY JOURNAL; REPRODUCIBILITY; SCINTIGRAPHY;

ADHESIVENESS; ADMINISTRATION, INHALATION; AEROSOLS; ALBUTEROL; BRONCHODILATOR AGENTS; BUDESONIDE; CHEMISTRY, PHARMACEUTICAL; DRUG CARRIERS; EQUIPMENT DESIGN; LACTOSE; NEBULIZERS AND VAPORIZERS; PARTICLE SIZE; POWDERS; SURFACE PROPERTIES; TIME FACTORS;

EID: 33344461705     PISSN: 03785173     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijpharm.2005.11.029     Document Type: Article

References (31)

1. Arnold, K., Knecht, A., Roos, R., Sluke, G., Thieme, H., Wenzel, J., 1995. Powders for inhalation. US-patent 5,478,578.
2. J.H. Bell, P.S. Hartley, and J.S.G. Cox Dry powder aerosols I: a new powder inhalation device J. Pharm. Sci. 60 1971 1559 1564
3. A.H. de Boer, P. Hagedoorn, D. Gjaltema, D. Lambregts, M. Irngartinger, and H.W. Frijlink The rate of drug particle detachment from carrier crystals in an air classifier based inhaler Pharm. Res. 21 2004 2158 2166
4. A.H. de Boer, P. Hagedoorn, D. Gjaltema, D. Lambregts, M. Irngartinger, and H.W. Frijlink The mode of drug particle detachment from carrier crystals in an air classifier based inhaler Pharm. Res. 21 2004 2167 2174
5. A.H. de Boer, B.H.J. Dickhoff, P. Hagedoorn, D. Gjaltema, J. Goede, D. Lambregts, and H.W. Frijlink A critical evaluation of the relevant parameters for drug redispersion from adhesive mixtures during inhalation Int. J. Pharm. 294 2005 173 184
6. ® multi-dose dry powder inhaler. Int. J. Pharm. 310, 72-80.
7. P. Brand, T. Meyer, S. Häussermann, M. Schulte, G. Scheuch, T. Bernhard, B. Sommerauer, N. Weber, and M. Griese Optimum peripheral drug deposition in patients with cystic fibrosis J. Aerosol Med. 18 2005 45 54
8. B.H.J. Dickhoff, A.H. de Boer, D. Lambregts, and H.W. Frijlink The effect of carrier surface and bulk properties on drug particle detachment from crystalline lactose carrier particles during inhalation, as function of carrier payload and mixing time Eur. J. Pharm. Biopharm. 56 2003 291 302
9. B.H.J. Dickhoff, A.H. de Boer, D. Lambregts, and H.W. Frijlink The interaction between carrier rugosity and carrier payload and its effect on drug particle redispersion from adhesive mixtures during inhalation Eur. J. Pharm. Biopharm. 59 2004 197 205
10. T. Ehtezazi, M.A. Horsfield, P.W. Barry, and C. O'Callaghan Dynamic change of the upper airway during inhalation via aerosol delivery devices J. Aerosol Med. 17 2004 325 333
11. T. Ehtezazi, K.W. Southern, D. Allanson, I. Jenkinson, and C. O'Callaghan Suitability of the upper airway models obtained from MRI studies in simulating drug lung deposition from inhalers Pharm. Res. 22 2005 166 170
12. T. Ehtezazi, M.A. Horsfield, P.W. Barry, P. Goodenough, and C. O'Callaghan Effect of device inhalational resistance on the three-dimensional configuration of the upper airway J. Pharm. Sci. 94 2005 1418 1426
13. H.W. Frijlink, and A.H. de Boer Dry powder inhalers for pulmonary drug delivery Expert Opin. Drug Deliv. 1 2004 67 86
14. T.R. Gerrity Pathophysiological and disease constraints on aerosol delivery P.R. Byron Respiratory drug delivery 1990 CRC Press Boca Raton, USA 1 38
15. G.W. Hallworth, and U.G. Andrews Size analysis of suspension inhalation aerosols by inertial separation methods J. Pharm. Pharmac. 28 1976 898 907
16. Y. Kawashima, T. Serigano, T. Hino, H. Yamamoto, and H. Takeuchi Effect of surface morphology of carrier lactose on dry powder inhalation property of pranlukast hydrate Int. J. Pharm. 172 1998 179 188
17. M.D. Louey, and P.J. Stewart Particle interactions involved in aerosol dispersion of ternary interactive mixtures Pharm. Res. 19 2002 1524 1531
18. T.B. Martonen, I. Katz, K. Fults, and A.J. Hickey Use of analytically defined estimates of aerosol respirable fraction to predict lung deposition patterns Pharm. Res. 9 1992 1634 1639
19. B.J. Meakin, D. Ganderton, I. Panza, and P. Ventura The effect of flow rate on drug delivery from the Pulvinal, a high-resistance dry powder inhaler J. Aerosol Med. 11 1998 143 152
20. S.P. Newman, G.R. Pitcairn, P.H. Hirst, R.E. Bacon, E. O'Keefe, M. Reiners, and R. Hermann Scintigraphic comparison of budesonide deposition from two dry powder inhalers Eur. Respir. J. 16 2000 178 183
21. F. Podczeck The influence of particle size distribution and surface roughness of carrier particles on the in vitro properties of dry powder inhalers Aerosol Sci. Technol. 31 1999 310 321
22. M. Reiners, N. Stang, and E. Wolf-Heuss Stability and performance characteristics of a budesonide powder formulation for inhalation N.D. Dalby P.R. Byron S.J. Farr J. Peart Respiratory Drug Delivery VII 2000 Serentec Press Raleigh 333 336
23. H. Steckel, and B.W. Müller In vitro evaluation of dry powder inhalers II: influence of carrier particle size and concentration on in vitro deposition Int. J. Pharm. 154 1997 31 37
24. H. Steckel, M. Borowski, and F. Eskandar Selecting lactose for a capsule based dry powder inhaler Pharm. Technol. Eur. 4 2004 23 35
25. ® dry powder inhaler: focussed in vitro proof of principle evaluation of a new chemical entity for asthma Int. J. Pharm. 239 2002 149 156
26. United States Pharmacopeia 27, 2004.
27. M. Weda, P. Zanen, A.H. de Boer, D. Gjaltema, A. Ajaoud, D.M. Barends, and H.W. Frijlink Equivalence testing of salbutamol dry powder inhalers: in vitro impaction results versus in vivo efficacy Int. J. Pharm. 249 2002 247 255
28. M. Weda, P. Zanen, A.H. de Boer, D.M. Barends, and H.W. Frijlink An investigation into the predictive value of cascade impactor results for side effects in inhaled salbutamol Int. J. Pharm. 287 2004 79 87
29. X.M. Zeng, G.P. Martin, S.-K. Tee, and C. Marriott The role of fine particle lactose on the dispersion and deaggregation of salbutamol sulphate in an air stream in vitro Int. J. Pharm. 176 1998 99 110
30. X.M. Zeng, G.P. Martin, C. Marriott, and J. Pritchard Lactose as carrier in dry powder formulations: the influence of surface characteristics on drug delivery J. Pharm. Sci. 90 2001 1424 1434
31. X.M. Zeng, D. O'Leary, M. Phelan, S. Jones, and J. Colledge Delivery of salbutamol and of budesonide from a novel multi-dose inhaler Airmax™ Resp. Med. 96 2002 404 411